MCID: GLC036
MIFTS: 48

Glucagonoma

Categories: Rare diseases, Gastrointestinal diseases, Endocrine diseases

Aliases & Classifications for Glucagonoma

Summaries for Glucagonoma

MalaCards based summary : Glucagonoma, also known as glucagonoma syndrome, is related to pheochromocytoma and pancreatic neuroendocrine tumor, and has symptoms including neoplasm of the pancreas, glossitis and diabetes mellitus. An important gene associated with Glucagonoma is SST (Somatostatin), and among its related pathways/superpathways are G alpha (s) signalling events and Gastric acid production. The drugs Pancreatic Polypeptide and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include pancreas, liver and skin.

Wikipedia : 72 A glucagonoma is a rare tumor of the alpha cells of the pancreas that results in the overproduction of... more...

Related Diseases for Glucagonoma

Diseases related to Glucagonoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 109)
id Related Disease Score Top Affiliating Genes
1 pheochromocytoma 27.8 CHGA CHGB SST VIP
2 pancreatic neuroendocrine tumor 11.3
3 appendiceal l-cell glucagon-like peptide producing tumor 10.8
4 primary syphilis 10.4 CHGA SST
5 bone giant cell sarcoma 10.4 CHGA SST
6 renal pelvis carcinoma 10.4 CHGA SST
7 rete ovarii cystadenofibroma 10.4 CHGA SST
8 tooth erosion 10.3 SCT SST
9 protein s deficiency 10.3 GHRH SST
10 bile duct cystadenocarcinoma 10.3 SCT SST
11 paraganglioma 10.3 CHGA SST
12 pancreatitis 10.3
13 peripheral degeneration of cornea 10.3 SCT SST
14 lactose intolerance 10.3 SCT SST
15 male reproductive organ benign neoplasm 10.3 CHGA SST
16 cardiovascular organ benign neoplasm 10.3 GHRH SST
17 neurogenic arthropathy 10.3 GHRH SST
18 acute myocarditis 10.3 GHRH SST
19 extrinsic cardiomyopathy 10.3 CHGA SST
20 wegmann jones smith syndrome 10.3 SST VIP
21 chondroma 10.3 SCT SST
22 adrenal cortex disease 10.3 GHRH SST
23 intestinal volvulus 10.3 SST VIP
24 opitz-gbbb syndrome 10.2 CHGA SST
25 uterine ligament clear cell adenocarcinoma 10.2 GHRH SST
26 motility-related diarrhea 10.2 SST VIP
27 retinal vascular occlusion 10.2 SCT SST
28 drug psychosis 10.2 SST VIP
29 medullary thyroid carcinoma, familial 10.2 CHGA SST
30 tricuspid valve prolapse 10.2 CHGA VIP
31 alpha-methylacyl-coa racemase deficiency 10.1 SST VIP
32 cavernous hemangioma 10.1 CHGA VIP
33 usher syndrome, type 1f 10.1 GHRH SST
34 hyperparathyroidism, familial primary 10.1 CHGA SCT
35 male reproductive system disease 10.1 SCT VIP
36 sweat gland cancer 10.1 SST VIP
37 insulinoma 10.1
38 tropical calcific pancreatitis 10.1 SCT SST
39 lung cancer susceptibility 2 10.0 GHRH SST
40 multiple endocrine neoplasia 10.0
41 cryoglobulinemia 10.0 SCT SST
42 clostridium difficile colitis 10.0 CHGA CHGB
43 hepatitis 10.0
44 tuberculum sellae meningioma 9.9 SCT SST
45 carcinoma of unknown primary site, childhood 9.9 CHGA GHRH SST
46 atypical polypoid adenomyoma 9.9 SCT SST
47 primary progressive multiple sclerosis 9.9 CHGA SCT SST
48 volkmann contracture 9.9 CHGA SCT SST
49 acquired aneurysmal subarachnoid hemorrhage 9.9 CHGA GHRH SST
50 intraocular lymphoma 9.9 CHGA SCT SST

Graphical network of the top 20 diseases related to Glucagonoma:



Diseases related to Glucagonoma

Symptoms & Phenotypes for Glucagonoma

Human phenotypes related to Glucagonoma:

56 32 (show all 42)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neoplasm of the pancreas 56 32 hallmark (90%) Very frequent (99-80%) HP:0002894
2 glossitis 56 32 frequent (33%) Frequent (79-30%) HP:0000206
3 diabetes mellitus 56 32 frequent (33%) Frequent (79-30%) HP:0000819
4 skin rash 56 32 frequent (33%) Frequent (79-30%) HP:0000988
5 pruritus 56 32 frequent (33%) Frequent (79-30%) HP:0000989
6 weight loss 56 32 frequent (33%) Frequent (79-30%) HP:0001824
7 normochromic anemia 56 32 frequent (33%) Frequent (79-30%) HP:0001895
8 acanthocytosis 56 32 frequent (33%) Frequent (79-30%) HP:0001927
9 diarrhea 56 32 frequent (33%) Frequent (79-30%) HP:0002014
10 nausea and vomiting 56 32 frequent (33%) Frequent (79-30%) HP:0002017
11 constipation 56 32 frequent (33%) Frequent (79-30%) HP:0002019
12 anorexia 56 32 frequent (33%) Frequent (79-30%) HP:0002039
13 hepatomegaly 56 32 frequent (33%) Frequent (79-30%) HP:0002240
14 episodic abdominal pain 56 32 frequent (33%) Frequent (79-30%) HP:0002574
15 poor appetite 56 32 frequent (33%) Frequent (79-30%) HP:0004396
16 abnormal blistering of the skin 56 32 frequent (33%) Frequent (79-30%) HP:0008066
17 stomatitis 56 32 frequent (33%) Frequent (79-30%) HP:0010280
18 chronic fatigue 56 32 frequent (33%) Frequent (79-30%) HP:0012432
19 depression 56 32 occasional (7.5%) Occasional (29-5%) HP:0000716
20 intermittent jaundice 56 32 occasional (7.5%) Occasional (29-5%) HP:0001046
21 intrahepatic cholestasis 56 32 occasional (7.5%) Occasional (29-5%) HP:0001406
22 ascites 56 32 occasional (7.5%) Occasional (29-5%) HP:0001541
23 thromboembolism 56 32 occasional (7.5%) Occasional (29-5%) HP:0001907
24 gastrointestinal hemorrhage 56 32 occasional (7.5%) Occasional (29-5%) HP:0002239
25 steatorrhea 56 32 occasional (7.5%) Occasional (29-5%) HP:0002570
26 intestinal obstruction 56 32 occasional (7.5%) Occasional (29-5%) HP:0005214
27 extrahepatic cholestasis 56 32 occasional (7.5%) Occasional (29-5%) HP:0012334
28 lack of bowel sounds 56 32 occasional (7.5%) Occasional (29-5%) HP:0030145
29 abnormal gastrointestinal motility 56 32 occasional (7.5%) Occasional (29-5%) HP:0030895
30 abnormality of the thyroid gland 56 32 very rare (1%) Very rare (<4-1%) HP:0000820
31 increased circulating gonadotropin level 56 32 very rare (1%) Very rare (<4-1%) HP:0000837
32 growth hormone excess 56 32 very rare (1%) Very rare (<4-1%) HP:0000845
33 prolactin excess 56 32 very rare (1%) Very rare (<4-1%) HP:0000870
34 subcutaneous lipoma 56 32 very rare (1%) Very rare (<4-1%) HP:0001031
35 pituitary adenoma 56 32 very rare (1%) Very rare (<4-1%) HP:0002893
36 parathyroid adenoma 56 32 very rare (1%) Very rare (<4-1%) HP:0002897
37 hypercalcemia 56 32 very rare (1%) Very rare (<4-1%) HP:0003072
38 primary hyperparathyroidism 56 32 very rare (1%) Very rare (<4-1%) HP:0008200
39 adrenocortical adenoma 56 32 very rare (1%) Very rare (<4-1%) HP:0008256
40 abnormality of the abdomen 56 Occasional (29-5%)
41 hypercortisolism 56 Very rare (<4-1%)
42 increased circulating cortisol level 32 very rare (1%) HP:0003118

UMLS symptoms related to Glucagonoma:


diarrhea

Drugs & Therapeutics for Glucagonoma

Drugs for Glucagonoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 99)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1 Pancreatic Polypeptide Investigational Phase 4,Phase 2,Phase 3,Phase 1 59763-91-6
2 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
3
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
4
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
5
Levoleucovorin Approved Phase 2, Phase 3,Phase 1 68538-85-2
6
Oxaliplatin Approved, Investigational Phase 2, Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
9
leucovorin Approved, Nutraceutical Phase 2, Phase 3, Phase 1 58-05-9 143 6006
10 Angiogenesis Inhibitors Phase 2, Phase 3,Phase 1
11 Angiogenesis Modulating Agents Phase 2, Phase 3,Phase 1
12 Antimetabolites Phase 2, Phase 3,Phase 1
13 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 1
14 Immunosuppressive Agents Phase 2, Phase 3,Phase 1
15 Adjuvants, Anesthesia Phase 3
16 Analgesics Phase 3
17 Analgesics, Opioid Phase 3
18 Anesthetics Phase 3
19 Anesthetics, General Phase 3
20 Anesthetics, Intravenous Phase 3
21 Central Nervous System Depressants Phase 3
22 Narcotics Phase 3
23 Peripheral Nervous System Agents Phase 3
24 Folate Nutraceutical Phase 2, Phase 3
25 Vitamin B9 Nutraceutical Phase 2, Phase 3
26 Cola Nutraceutical Phase 3,Phase 2,Phase 1
27
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
28
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
29
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
30
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
31
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
32
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
33
Capecitabine Approved, Investigational Phase 2,Phase 1 154361-50-9 60953
34
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
35
Streptozocin Approved Phase 2 18883-66-4 29327
36
Octreotide Approved, Investigational Phase 2,Phase 1 83150-76-9 383414 6400441
37
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
38
Pancrelipase Approved Phase 2,Phase 1 53608-75-6
39
Melphalan Approved Phase 2 148-82-3 4053 460612
40
Somatostatin Approved Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
41
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
42
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
43
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
44
Gemcitabine Approved Phase 2 95058-81-4 60750
45
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
46
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
47
Nicotinamide Approved, Nutraceutical Phase 2 98-92-0 936
48
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 11103-57-4, 68-26-8 445354
49
Vatalanib Investigational Phase 2,Phase 1 212141-54-3 151194
50 Anti-Bacterial Agents Phase 2,Phase 1

Interventional clinical trials:

(show all 34)

id Name Status NCT ID Phase Drugs
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3 5-fluorouracil;leucovorin;oxaliplatin
3 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
4 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
5 Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00131911 Phase 2 sorafenib tosylate
6 Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors Completed NCT00075439 Phase 2 gefitinib
7 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
8 PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00017199 Phase 2 bortezomib
9 Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors Completed NCT00602082 Phase 2 capecitabine;cisplatin;streptozocin
10 AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors Completed NCT00427349 Phase 2 AMG 706;octreotide
11 Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery Completed NCT00416767 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
12 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2 isolated perfusion;melphalan
13 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors Completed NCT00027638 Phase 2 thalidomide
14 Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors Recruiting NCT02259725 Phase 2 regorafenib
15 Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01824875 Phase 2 temozolomide;capecitabine
16 Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525082 Phase 2 capecitabine;temozolomide
17 Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery Terminated NCT02031536 Phase 2 everolimus
18 Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors Terminated NCT00084461 Phase 2 romidepsin
19 Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer Terminated NCT02273752 Phase 2 Everolimus
20 Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy Terminated NCT01056601 Phase 2 Bortezomib;Panobinostat
21 Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors Terminated NCT00466856 Phase 2 octreotide acetate
22 Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors Withdrawn NCT02108782 Phase 2 dovitinib lactate
23 Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors Withdrawn NCT00227773 Phase 2 octreotide acetate;vatalanib
24 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
25 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
26 Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer Completed NCT00006368 Phase 1
27 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
28 Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer Completed NCT00005842 Phase 1 tipifarnib
29 Laser Tissue Welding - Distal Pancreatectomy Sealing Study Recruiting NCT03147768 Phase 1
30 Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors Active, not recruiting NCT00655655 Phase 1 everolimus;vatalanib
31 Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer Terminated NCT00002947 Phase 1
32 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
33 Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan Enrolling by invitation NCT02102893
34 Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors Terminated NCT00730483 PVA microporous hydrospheres/doxorubicin hydrochloride

Search NIH Clinical Center for Glucagonoma

Genetic Tests for Glucagonoma

Genetic tests related to Glucagonoma:

id Genetic test Affiliating Genes
1 Glucagonoma 29

Anatomical Context for Glucagonoma

MalaCards organs/tissues related to Glucagonoma:

39
Pancreas, Liver, Skin, Bone, Pituitary, Endothelial, Breast

Publications for Glucagonoma

Articles related to Glucagonoma:

(show top 50) (show all 303)
id Title Authors Year
1
Necrolytic migratory erythema associated with glucagonoma treated successfully with cyclosporine. ( 28508546 )
2017
2
Glucagonoma-Associated Rash. ( 28273025 )
2017
3
Foxa2, a novel protein partner of the tumour suppressor menin, is deregulated in mouse and human MEN1 glucagonomas. ( 28188614 )
2017
4
Necrolytic migratory erythema: A diagnostic clue in glucagonoma syndrome. ( 27567335 )
2017
5
Glucagonoma syndrome: a review and update on treatment. ( 27422767 )
2016
6
Glucagonoma syndrome: report of one case. ( 28138636 )
2016
7
Necrolytic migratory erythema and pancreatic glucagonoma. ( 27622478 )
2016
8
Paediatric necrolytic migratory erythema as a presenting sign of glucagonoma syndrome. ( 26585841 )
2016
9
Glucagonoma and Glucagonoma Syndrome: A Case Report with Review of Recent Advances in Management. ( 26981306 )
2016
10
Glucagonoma syndrome associated with necrolytic migratory erythema. ( 26248239 )
2015
11
Delayed diagnosis of glucagonoma syndrome: a case report. ( 26679842 )
2015
12
Glucagonoma Pancreatic Neuroendocrine Tumor Treated With 177Lu DOTATATE Induction and Maintenance Peptide Receptor Radionuclide Therapy. ( 26204206 )
2015
13
Proposed Radiation Induced Hormone Crisis in a Patient with Glucagonoma. ( 26493062 )
2015
14
Glucagon receptor gene mutations with hyperglucagonemia but without the glucagonoma syndrome. ( 25914784 )
2015
15
A Novel Missense Mutation of the MEN1 Gene in a Patient with Multiple Endocrine Neoplasia Type 1 with Glucagonoma and Obesity. ( 26424307 )
2015
16
Glucagonoma syndrome: A case report. ( 26622635 )
2015
17
Reversal of dilated cardiomyopathy after glucagonoma excision. ( 25553769 )
2015
18
Imaging features of glucagonoma syndrome: A case report and review of the literature. ( 25789004 )
2015
19
Paradoxical presentation of glucagonoma with delayed onset of necrolytic migratory erythema. ( 25448171 )
2015
20
Glucagonoma-induced acute heart failure. ( 25520848 )
2014
21
Glucagonoma syndrome: a case report with focus on skin disorders. ( 25152626 )
2014
22
Non-secreting benign glucagonoma diagnosed incidentally in a patient with refractory thrombocytopenic thrombotic purpura: report of a case. ( 25373364 )
2014
23
Rapid improvement of glucagonoma-related necrolytic migratory erythema with octreotide. ( 26183746 )
2014
24
Novel mutation 928G>C of MEN1 gene in a familial multiple endocrine neoplasia type 1 case (MEN1) with co-existence of insulinoma and glucagonoma. ( 25047095 )
2014
25
Pancreatic glucagonoma metastasising to the right ovary five years after initial surgery: a case report. ( 24018597 )
2013
26
Pancreatic glucagonoma with pancreatic calcification. ( 23719610 )
2013
27
Necrolytic migratory erythema and glucagonoma rising from pancreatic head. ( 23890147 )
2013
28
Enhanced glucagon-like peptide-1 secretion in a patient with glucagonoma: implications for glucagon-like peptide-1 secretion from pancreatic I+ cells in vivo. ( 24008099 )
2013
29
Putting the pieces together: necrolytic migratory erythema and the glucagonoma syndrome. ( 23681843 )
2013
30
Glucagonoma with necrolytic migratory erythema exhibiting responsiveness to subcutaneous octreotide injections. ( 23389434 )
2013
31
Necrolytic migratory erythema as the first manifestation of glucagonoma. ( 22970401 )
2012
32
Bone lesions in recurrent glucagonoma: A case report and review of literature. ( 22737277 )
2012
33
Necrolytic migratory erythema associated with glucagonoma syndrome diagnosed by (68) Ga-DOTANOC PET-CT. ( 23279825 )
2012
34
An unusual case of subclinical diffuse glucagonoma coexisting with two nodules in the pancreas: characteristic features on computed tomography. ( 22239827 )
2012
35
Is necrolytic migratory erythema due to glucagonoma a misnomer? A more apt name might be mucosal and intertriginous erosive dermatitis. ( 22513058 )
2012
36
Functioning glucagonoma associated with primary hyperparathyroidism: multiple endocrine neoplasia type 1 or incidental association? ( 23259638 )
2012
37
Hypercalcemia appeared in a patient with glucagonoma treated with octreotide acetate long-acting release. ( 23062642 )
2012
38
A case of a giant glucagonoma with parathyroid hormone-related peptide secretion showing an inconsistent postsurgical endocrine status. ( 21841327 )
2011
39
Glucagonoma and the glucagonoma syndrome - cumulative experience with an elusive endocrine tumour. ( 21470282 )
2011
40
Foetal proglucagon processing in relation to adult appetite control: lessons from a transplantable rat glucagonoma with severe anorexia. ( 21824258 )
2011
41
Glucagonoma syndrome: a case report. ( 21859461 )
2011
42
Diabetes Cured by Pancreaticoduodenectomy: A Case Report of Glucagonoma Masquerading as Carcinoma of the Head of Pancreas. ( 22086709 )
2011
43
Glucagon cell adenomatosis: a new entity associated with necrolytic migratory erythema and glucagonoma syndrome. ( 21763589 )
2011
44
A case of pancreatic glucagonoma with erythema. ( 20530930 )
2010
45
Necrolytic migratory erythema due to glucagonoma. ( 20060072 )
2010
46
Glucagonoma syndrome and necrolytic migratory erythema. ( 20465606 )
2010
47
Successful treatment of canine necrolytic migratory erythema (superficial necrolytic dermatitis) due to metastatic glucagonoma with octreotide. ( 20500495 )
2010
48
[Glucagonoma without glucagonoma syndrome]. ( 20499510 )
2010
49
Necrolytic migratory erythema associated with glucagonoma syndrome. ( 20530273 )
2010
50
Necrolytic migratory erythaema and glucagonoma syndrome. ( 19317246 )
2009

Variations for Glucagonoma

Expression for Glucagonoma

Search GEO for disease gene expression data for Glucagonoma.

Pathways for Glucagonoma

Pathways related to Glucagonoma according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.3 GHRH SCT VIP
2 9.47 SCT VIP

GO Terms for Glucagonoma

Cellular components related to Glucagonoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.46 CHGA GHRH SCT SST
2 extracellular region GO:0005576 9.1 CHGA CHGB GHRH SCT SST VIP
3 secretory granule GO:0030141 8.96 CHGA CHGB

Biological processes related to Glucagonoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of cAMP biosynthetic process GO:0030819 8.62 GHRH SCT

Molecular functions related to Glucagonoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.92 CHGB SCT SST VIP

Sources for Glucagonoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....